GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » 10-Year RORE %

Theralase Technologies (TSXV:TLT) 10-Year RORE % : -11.08% (As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Theralase Technologies's 10-Year RORE % for the quarter that ended in Dec. 2024 was -11.08%.

The industry rank for Theralase Technologies's 10-Year RORE % or its related term are showing as below:

TSXV:TLT's 10-Year RORE % is ranked worse than
68.35% of 417 companies
in the Medical Devices & Instruments industry
Industry Median: -0.21 vs TSXV:TLT: -11.08

Theralase Technologies 10-Year RORE % Historical Data

The historical data trend for Theralase Technologies's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies 10-Year RORE % Chart

Theralase Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.93 -2.29 -3.27 -2.91 -11.08

Theralase Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.91 -3.67 -6.19 -9.30 -11.08

Competitive Comparison of Theralase Technologies's 10-Year RORE %

For the Medical Devices subindustry, Theralase Technologies's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies's 10-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's 10-Year RORE % falls into.



Theralase Technologies 10-Year RORE % Calculation

Theralase Technologies's 10-Year RORE % for the quarter that ended in Dec. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.019--0.063 )/( -0.397-0 )
=0.044/-0.397
=-11.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 10-year before.


Theralase Technologies  (TSXV:TLT) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Theralase Technologies 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 3rd Quarter Trades of CADINHA & CO LLC

By GuruFocus Research GuruFocus Editor 10-22-2022

Top 5 4th Quarter Trades of Rothschild Capital Partners, LLC

By GuruFocus Research GuruFocus Editor 02-15-2023

Top 5 2nd Quarter Trades of SYNOVUS FINANCIAL CORP

By GuruFocus Research GuruFocus Editor 08-11-2022

Top 5 3rd Quarter Trades of Checchi Capital Advisers, LLC

By GuruFocus Research GuruFocus Editor 11-10-2022

Top 5 4th Quarter Trades of VANTAGEPOINT INVESTMENT ADVISERS LLC

By GuruFocus Research GuruFocus Editor 01-21-2023

Top 5 2nd Quarter Trades of K.J. Harrison & Partners Inc

By GuruFocus Research GuruFocus Editor 07-27-2022

Top 5 4th Quarter Trades of Financial Sense Advisors, Inc.

By GuruFocus Research GuruFocus Editor 02-07-2023

Top 5 3rd Quarter Trades of Eqis Capital Management, Inc.

By GuruFocus Research GuruFocus Editor 10-24-2022

Matrix Trust Co Buys 2, Sells 3 in 2nd Quarter

By GuruFocus Research GuruFocus Editor 08-03-2022